The Claim
In patients with homozygous familial hypercholesterolemia of Saudi Arabian origin, monthly administration of Evolocumab 420 mg is associated with a non-significant reduction in LDL cholesterol levels, decreasing from 11.79 to 10.95 mmol/L (p=0.063), indicating limited efficacy of this treatment regimen in this genetically defined population.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
For people in Saudi Arabia with a rare inherited form of very high cholesterol, taking a drug called Evolocumab once a month didn’t seem to lower their bad cholesterol much — the drop was small and not strong enough to be sure it wasn’t just by chance.
See the scientific wording
In patients with homozygous familial hypercholesterolemia of Saudi Arabian origin, monthly dosing of Evolocumab 420 mg is associated with a non-significant trend toward reduced LDL-C levels (from 11.79 to 10.95 mmol/L, p=0.063), suggesting limited efficacy of this regimen in this genetically defined group.
What the research says
1 studyThe study looked at the same medicine, dose, and group of patients as the claim, and found the same small, not statistically significant drop in bad cholesterol.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.